Fire1

Fire1

Dublin, Ireland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Fire1, founded in 2014 and headquartered in Dublin, Ireland, is a private medical device innovator targeting the global heart failure market. The company's lead product, NORM, is a remote monitoring system comprising an implantable IVC sensor, a wearable belt, and a smartphone app, designed to provide patients and clinicians with daily fluid status data. Currently in clinical trials across the US and Europe, Fire1 aims to reduce hospitalizations and give patients greater independence. The company originated from The Foundry, a prominent medical device incubator in Menlo Park, California.

Cardiovascular

Technology Platform

The NORM platform is a remote patient monitoring system for heart failure. It consists of an implantable sensor placed in the inferior vena cava (IVC) to directly measure fluid volume status, a wearable belt for daily wireless data transmission, and a smartphone app for patient and clinician data access and alerts.

Opportunities

The massive and growing global heart failure population, coupled with the high cost of hospitalizations, creates a multi-billion-dollar market for solutions that enable proactive care.
The shift towards value-based healthcare and remote patient monitoring provides a strong tailwind for the adoption of technologies like NORM that aim to reduce costly clinical events.

Risk Factors

Key risks include clinical trial failure, regulatory rejection, challenges in achieving market adoption and reimbursement, and competition from established and emerging heart failure monitoring technologies.
As a pre-revenue company, Fire1 is also dependent on securing ongoing financing.

Competitive Landscape

Fire1 competes in the remote patient monitoring space for heart failure, which includes incumbent devices like Abbott's CardioMEMS (measures pulmonary artery pressure) and a growing array of non-invasive wearables and algorithmic software platforms. NORM's differentiation is its direct measurement of IVC diameter as a proxy for fluid volume, a novel approach compared to indirect metrics.